Consensus ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
61.66 ^USD	-0.08%		-4.88%	+11.82%

May. 21	Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing	MT
May. 20	ANI Pharmaceuticals Launches Kionex Suspension	MT

Evolution of the average Target Price on ANI Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

39f28e526dde43ed.DzFCxRBO6ftR9eXyHWL4sp9PMYyrQqpJ7Nn_ML1yyS8.PWly_Ht2hrUestPBQgOS9sh7U_rbFNAguuiFZfRCgk5tXQayJX6LqiiUvA~de67ee515de7c9301f80ae21819afdea

Analyst Recommendations on ANI Pharmaceuticals, Inc.

Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing	May. 21	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing	May. 16	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing	May. 03	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	Apr. 17	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,345,000, According to a Recent SEC Filing	Apr. 03	MT
Capital One Initiates ANI Pharmaceuticals at Overweight Rating	Mar. 15	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $83 From $73, Maintains Buy Rating	Mar. 04	MT
Truist Securities Raises Price Target on ANI Pharmaceuticals to $80 From $72, Maintains Buy Rating	Mar. 01	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $72 From $70, Maintains Buy Rating	Feb. 16	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $73 From $60, Maintains Buy Rating	23-08-22	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $62 From $59, Keeps Buy Rating	23-07-27	MT
Truist Adjusts ANI Pharmaceuticals' Price Target to $60 From $52, Keeps Buy Rating	23-07-21	MT
Guggenheim Adjusts Price Target on ANIP to $59 From $55, Maintains Buy Rating	23-05-09	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $52 From $50, Maintains Buy Rating	23-05-09	MT
Raymond James Adjusts Price Target on ANI Pharmaceuticals to $49 From $48, Maintains Outperform Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $60 From $53, Keeps Buy Rating	23-05-09	MT
Cantor Fitzgerald Adjusts ANI Pharmaceuticals Price Target to $42 From $40, Maintains Neutral Rating	23-05-08	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $53 From $50, Keeps Buy Rating	23-03-13	MT
Cosette Pharmaceuticals, Inc. Launches Betaine Anhydrous Powder, AB-rated to Cystadane (Betaine Anhydrous for Oral Solution)	23-03-02	CI
HC Wainwright Starts ANI Pharmaceuticals at Buy With $50 Price Target	22-09-07	MT
S&P Revises ANI Pharmaceuticals Outlook To Stable From Positive On Increased Expenses; 'B+' Ratings Affirmed	22-08-29	MT
Raymond James Adjusts ANI Pharmaceuticals' Price Target to $47 From $65, Keeps Outperform Rating	22-03-16	MT
Raymond James Adjusts ANI Pharmaceuticals' Price Target to $65 from $60, Keeps Outperform Rating	21-11-02	MT
Truist Securities Starts ANI Pharmaceuticals at Buy With $70 Price Target	21-11-02	MT